Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,572 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Completed Phase 1 Interventional

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

NCT03362723
View directory record Official record
Conditions
Solid Tumors
Interventions
Idasanutlin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Probenecid on Pexidartinib Pharmacokinetics

NCT03138759
View directory record Official record
Conditions
Pharmacokinetics in Healthy Volunteers
Interventions
Pexidartinib, Probenecid
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

NCT04441255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06690138
View directory record Official record
Conditions
Healthy Participants
Interventions
Divarasib, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

NCT00117676
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
17
States / cities
La Jolla, California • Pasadena, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

NCT03586414
View directory record Official record
Conditions
Diastolic Dysfunction
Interventions
MITOQUINOL MESYLATE then placebo, Placebo, then MITOQUINOL MESYLATE
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Not applicable Interventional

Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome

NCT05083416
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Prolonged Nightly Fasting, Regular Eating pattern
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting Phase 2 Interventional

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

NCT05910528
View directory record Official record
Conditions
Crohns Disease
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Recruiting Phase 2 Interventional

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

NCT06104592
View directory record Official record
Conditions
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
Radiation · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

NCT02336165
View directory record Official record
Conditions
Glioblastoma
Interventions
Durvalumab, Standard radiotherapy, Bevacizumab
Drug · Radiation · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

NCT06132867
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brigatinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

NCT05106153
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions
Suvorexant, Zolpidem, Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

NCT02521714
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

NCT05581758
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 510
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

NCT05137730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Personalized Mind-Body Intervention (MBI) for Improving Sleep Among Women Working in Healthcare

NCT05789212
View directory record Official record
Conditions
Sleep Insufficiency
Interventions
Personalized Trial ABCCBA, Personalized Trial CBAABC
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

NCT01301092
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
LY2189265
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

NCT05677867
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

NCT02781844
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
25mcg rhPTH(1-84), 50mcg rhPTH(1-84), 100mcg rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
North Hollywood, California • Indianapolis, Indiana • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 28, 2026, 11:08 PM EDT